Study examines adherence to colorectal cancer screening recommendations

April 9, 2012, JAMA and Archives Journals

Patients for whom colonoscopy was recommended were less likely to complete colorectal cancer screening than those patients for whom fecal occult blood testing (FOBT) was recommended or those patients who were given a choice between FOBT or colonoscopy, according to a study published in the April 9 issue of Archives of Internal Medicine, a JAMA Network publication.

Colorectal cancer (CRC) is a prevalent condition that can be diagnosed through screening and treated during an asymptomatic phase to prevent the morbidity and mortality associated with the unscreened clinical course of the disease, the authors write in their study background.

John M. Inadomi, M.D., of the University of Washington School of Medicine, Seattle, and colleagues conducted a to examine the effects of recommending FOBT, colonoscopy or giving patients at average risk for CRC a choice between the two.

A total of 997 racially and ethnically diverse were enrolled in the study conducted in the San Francisco Community Health Network, the public of the city and county of San Francisco. The mean (average) age of participants was 58.4 years and 53 percent of the participants were women.

Within 12 months of enrollment, 58 percent of the participants completed the CRC screening strategy they were assigned or chose. However, a significantly lower proportion of participants in the colonoscopy group completed that procedure (38.2 percent) compared with participants in the FOBT group completing that screening (67.2 percent) or those participants who were allowed to choose their screening (68.8 percent).

"There were significant racial/ethnic differences in screening completion, however, with whites more often completing colonoscopy and nonwhites more often completing FOBT," the authors comment.

African-Americans had the lowest CRC screening completion rate at 48 percent, while Asians at 60.7 percent and Latinos at 62.9 percent had the highest rates, the study results indicate.

The authors note that some of the differences appear to be driven by language preference. Participants who preferred to speak Spanish, Cantonese or Mandarin during their interviews were "significantly more likely" to adhere to CRC screening than participants of the same racial/ethnic groups who preferred to speak English.

"In summary, this study found that limiting the recommendation for CRC screening to colonoscopy can result in a lower completion rate for CRC screening compared with providing a choice between FOBT or colonoscopy, especially among ethnic/racial minorities," the authors conclude.

In an invited commentary, Theodore R. Levin, M.D., of Kaiser Permanente Medical Center, Walnut Creek, Calif., writes: "An important implication of this research is that the notion of 'preferred' CRC screening test should include both the physician's and the patient's perspective."

"If having too many choices leads to confusion, the study by Inadomi et al demonstrates that not having enough choice may lead to inaction when the only choice is colonoscopy. This study also shows that well-informed PCPs (primary care providers), focused on CRC screening, can have a meaningful impact on their patient's adherence with screening," Levin concludes. "When it comes to CRC , providing an option other than for our is not overwhelming, but necessary."

Explore further: Patient navigators appear to improve colorectal cancer screening rate in ethnically diverse patients

More information: Arch Intern Med. 2012;172[7]:575-582.
Arch Intern Med. 2012;172[7]:582-583.

Related Stories

Patient navigators appear to improve colorectal cancer screening rate in ethnically diverse patients

May 23, 2011
Among low-income patients who are black or whose primary language is not English, patient navigators may help improve colorectal cancer (CRC) screening rates, according to a report in the May 23 issue of Archives of Internal ...

Single flexible sigmoidoscopy screening associated with reduced colorectal cancer

August 18, 2011
A single flexible sigmoidoscopy screening between the ages of 55-64 years is associated with a lower level of colorectal cancer (CRC) incidence and mortality, according to a study published online August 18 in the Journal ...

Study examines whether age for initial screening colonoscopy should be different for men, women

September 27, 2011
An analysis of results of more than 40,000 screening colonoscopies finds that men have a higher rate of advanced tumors compared to women in all age groups examined, suggesting that the age that individuals should undergo ...

Recommended for you

New approach attacks 'undruggable' cancers from the outside in

January 23, 2018
Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer. However, many of the most common cancer-causing genes are so central to ...

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.